# EDGAR Filing Document

**Accession Number:** 0001795091
**File Stem:** 0001213900-25-104724
**Filing Date:** 2025-10
**Character Count:** 37587
**Document Hash:** 3523c921e88646a1783d9128f3c0e4ae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-104724.hdr.sgml**: 20251031

**ACCESSION NUMBER**: 0001213900-25-104724

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20251031

**DATE AS OF CHANGE**: 20251031

**EFFECTIVENESS DATE**: 20251031

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OS Therapies Inc
- **CENTRAL INDEX KEY:** 0001795091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825118368
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291202
- **FILM NUMBER:** 251441076

**BUSINESS ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 410-297-7793

**MAIL ADDRESS:**
- **STREET 1:** 15825 SHADY GROVE ROAD
- **STREET 2:** SUITE 135
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OS THERAPIES Inc
- **DATE OF NAME CHANGE:** 20191125

**As filed with the U.S. Securities and Exchange Commission on October 31, 2025**

**Registration No. 333-** 

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549<br>FORM S-8<br>REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933<br>OS THERAPIES INCORPORATED<br> (Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**82-5118368** |
| &nbsp;&nbsp;(State or other jurisdiction of<br> incorporation or organization) | &nbsp;&nbsp;(I.R.S. Employer<br> Identification No.) |
| &nbsp;&nbsp; **115 Pullman Crossing Road, Suite 103**<br> **Grasonville, Maryland** | &nbsp;&nbsp;**21638** |
| &nbsp;&nbsp;(Address of Principal Executive Offices) | &nbsp;&nbsp;(Zip Code) |

---

**2023 Incentive Compensation Plan**<br> (Full title of the plan)

**Paul A. Romness, MPH<br> President and Chief Executive Officer<br> OS Therapies Incorporated<br> 115 Pullman Crossing Road, Suite #103<br> Grasonville, Maryland 21638<br> (410) 297-7793**<br> (Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copies to:*

**Spencer G. Feldman, Esq.<br> Olshan Frome Wolosky LLP<br> 1325 Avenue of the Americas, 15<sup>th</sup> Floor<br> New York, New York 10019<br> (212) 451-2300**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by OS Therapies Incorporated (the "Company," "we," "us" and "our") for the purpose of registering an additional 6,000,000 shares of our common stock under the Company's 2023 Incentive Compensation Plan, as amended. The Company's Registration Statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1795091/000121390025002756/ea0227334-s8_ostherap.htm) (File No. 333-284242) filed with the Securities and Exchange Commission (the "SEC") on January 13, 2025 is incorporated by reference herein.

**PART I<br> INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The documents containing the information required by Item 1 and Item 2 of Part I of Form S-8 will be sent or given to employees as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act"). Such documents need not be filed with the SEC either as part of this registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in the registration statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II<br> INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents previously filed by us with the SEC under the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated herein by reference (other than any such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein, including any exhibits included with such Items):

● Our Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1795091/000121390025026238/ea0235597-10k_ostherap.htm) for the year ended December 31, 2024, filed with the SEC on March 31, 2025;

● Our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on [May 15, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025044336/ea0242061-10q_ostherap.htm) and [August 18, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025077916/ea0252948-10q_ostherap.htm) , respectively;

● Our Current Reports on Form 8-K (only to the extent "filed" and not "furnished"), filed with the SEC on [January 3, 2025](http://www.sec.gov/Archives/edgar/data/1795091/000121390025000844/ea0226635-8k_osthera.htm) , [January 14, 2025](http://www.sec.gov/Archives/edgar/data/1795091/000121390025003460/ea0227697-8k_osthera.htm) , [January 15, 2025](http://www.sec.gov/Archives/edgar/data/1795091/000121390025003886/ea0227757-8k_osthera.htm) , [January 29, 2025](http://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/ea0229055-8k_osthera.htm) , [April 2, 2025](http://www.sec.gov/Archives/edgar/data/1795091/000121390025027522/ea0236724-8k_ostherapies.htm) , [April 9, 2025](http://www.sec.gov/Archives/edgar/data/1795091/000121390025030375/ea0237768-8k_ostherapies.htm) , [April 15, 2025](http://www.sec.gov/Archives/edgar/data/1795091/000121390025032071/ea0238051-8k_ostherapies.htm) , [June 24, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025056911/ea0246590-8k_ostherap.htm) , [June 27, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025058603/ea0247272-8k_ostherap.htm) , [July 14, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025063479/ea0248754-8k_ostherap.htm) , [August 15, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025077431/ea0253338-8k_ostherap.htm) , [August 26, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025080484/ea0254579-8k_ostherap.htm) , [September 2, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025083396/ea0255568-8k_ostherap.htm) , [September 30, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025093936/ea0259321-8k_ostherap.htm) , [October 17, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025100019/ea0261257-8k_ostherapies.htm) and [October 21, 2025](https://www.sec.gov/Archives/edgar/data/1795091/000121390025100821/ea0261939-8k_ostherap.htm) ; and

● The description of our registered securities contained in [Exhibit 4.9](http://www.sec.gov/Archives/edgar/data/1795091/000121390025026238/ea023559701ex4-9_ostherap.htm) to our Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1795091/000121390025026238/ea0235597-10k_ostherap.htm) for the year ended December 31, 2024, filed with the SEC on March 31, 2025, including any amendment or reports filed for the purpose of updating this description.

All documents filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this Registration Statement (other than any such documents or portions thereof that are furnished under Item 2.02 or Item 7.01 of Form 8-K, unless otherwise indicated therein, including any exhibits included with such Items), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein or in any subsequently filed document that is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

Section 145 of the Delaware General Corporation Law (the "DGCL") authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys' fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys' fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

We have adopted provisions in our certificate of incorporation and bylaws that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:

● any breach of the director's duty of loyalty to us or our stockholders;

● any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

● any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or

● any transaction from which the director derived an improper personal benefit.

These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

In addition, our bylaws provide that:

● we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

● we will advance reasonable expenses, including attorneys' fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions

We have entered into separate indemnification agreements with each of our directors and executive officers. These agreements provide that we will indemnify each of our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys' fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person's services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director's or officer's services as a director referenced herein. Nonetheless, we will agree in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.

**Delaware Law**

Section 102 of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification will be made with respect to any claim, issue or matter as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court will deem proper.

**Third Amended and Restated Certificate of Incorporation**

Our third amended and restated certificate of incorporation provides that we are authorized to provide indemnification and advancement of expenses to our directors, officers and certain other covered persons to the fullest extent permitted by the DGCL. Our certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the DGCL and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions will not eliminate or limit the liability of any of our directors for:

● for any breach of the director's duty of loyalty to us or our stockholders;

● for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

● for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions; or

● for any transaction from which the director derived an improper personal benefit.

In addition, our third amended and restated certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, other than an action by or in the right of us, by reason of the fact that such person is or was a director or officer of the Company or is or was serving at the request of the Company as a director, officer, employee, general partner, agent or fiduciary of another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an "Indemnitee"), against all expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.

**Indemnification Agreements**

We have entered into separate indemnification agreements with each of our directors and executive officers. These indemnification agreements require us, among other things, to indemnify our directors and officers for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.

We maintain general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on their acts or omissions committed in their capacities as directors or officers.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

<br> ---

| | |
|:---|:---|
| **Exhibit <br> number** | **Description** |
| 3.1 | [Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated.<sup>(1)</sup>](https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex3-1_osthera.htm) |
| 3.2 | [Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated.<sup>(2)</sup>](https://www.sec.gov/Archives/edgar/data/1795091/000121390024050739/ea020576106ex3-2_ostherap.htm) |
| 3.3\* | [Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated.](ea026250401ex3-3_osthera.htm) |
| 3.3 | [Amended and Restated Bylaws of OS Therapies Incorporated.<sup>(1)</sup>](https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex3-3_osthera.htm) |
| 3.4 | [Amendment No. 1 to the Amended and Restated Bylaws of OS Therapies Incorporated.<sup>(3)</sup>](https://www.sec.gov/Archives/edgar/data/1795091/000121390025077431/ea025333801ex3-1_ostherap.htm) |
| 4.1 | [OS Therapies Incorporated 2023 Incentive Compensation Plan, as amended.<sup>(4)</sup>](https://www.sec.gov/Archives/edgar/data/1795091/000121390025100821/ea026193901ex10-1_ostherap.htm) |
| 5.1\* | [Opinion of Olshan Frome Wolosky LLP, as to the legality of the common stock.](ea026250401ex5-1_osthera.htm) |
| 23.1\* | [Consent of MaloneBailey, LLP, independent registered public accounting firm.](ea026250401ex23-1_osthera.htm) |
| 23.2\* | [Consent of Olshan Frome Wolosky LLP (included in the opinion filed as Exhibit 5.1).](ea026250401ex5-1_osthera.htm) |
| 24 | [Power of Attorney (set forth on signature page of the Registration Statement).](#a_001) |
| 107\* | [Calculation of Filing Fee Table.](ea026250401ex-fee_osthera.htm) |

---

(1) Incorporated herein by reference to the Company's Registration Statement on Form S-1
filed May 30, 2024 (File No. 333-279839).

(2) Incorporated herein by reference to Amendment No. 1 to the Company's Registration
Statement on Form S-1 filed June 7, 2024 (File No. 333-279839).

(3) Incorporated herein by reference to the Company's Current Report on Form 8-K
filed August 15, 2025.

(4) Incorporated herein by reference to the Company's Current Report on Form 8-K
filed October 21, 2025.

\* Filed herewith.

**Item 9. Undertakings.**

(a) The undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth
in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Filing
Fee Tables" or "Calculation of Registration Fee" table, as applicable, in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement;

*provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned registrant hereby undertakes that for the purpose of determining any liability under the Act, each filing of the registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act, and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Grasonville, State of Maryland on October 31, 2025.

---

| | |
|:---|:---|
| **OS THERAPIES INCORPORATED** | **OS THERAPIES INCORPORATED** |
| By: | /s/ Paul A. Romness, MPH |
|  | Paul A. Romness, MPH |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

We, the undersigned officers and directors of OS Therapies Incorporated hereby severally constitute and appoint Paul A. Romness, MPH and Christopher P. Acevedo, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Paul A. Romness, MPH | Chairman, President and Chief Executive Officer | October 31, 2025 |
| Paul A. Romness, MPH | (principal executive officer) |  |
| /s/ Christopher P. Acevedo | Chief Financial Officer | October 31, 2025 |
| Christopher P. Acevedo | (principal financial officer and principal accounting officer) |  |
| /s/ John Ciccio | Director | October 31, 2025 |
| John Ciccio |  |  |
| /s/ Avril McKean Dieser | Director | October 31, 2025 |
| Avril McKean Dieser |  |  |
| /s/ Karim Galzahr | Director | October 31, 2025 |
| Karim Galzahr |  |  |
| /s/ Olivier R. Jarry | Director | October 31, 2025 |
| Olivier R. Jarry |  |  |
| /s/ Theodore F. Search, Pharm.D. | Director | October 31, 2025 |
| Theodore F. Search, Pharm.D. |  |  |

---

## Exhibit 3.3

**Exhibit 3.3**

**CERTIFICATE OF AMENDMENT<br> TO THE**

**THIRD AMENDED AND RESTATED<br> CERTIFICATE OF INCORPORATION<br> OF<br> OS THERAPIES INCORPORATED**

 

*Pursuant to Section 242 of the General Corporation Law of the State of Delaware*

**OS THERAPIES INCORPORATED**, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the "<u>DGCL</u>"), does hereby certify:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The name of the corporation is: **<u>OS Therapies Incorporated</u>** (the "<u>Corporation</u>"). The Corporation was originally formed on April 12, 2018, as a Delaware limited liability company under the name OS Therapies LLC and converted into a Delaware corporation on June 5, 2019. The Corporation's original Certificate of Incorporation, Amended and Restated Certificate of Incorporation, Second Amended and Restated Certificate of Incorporation and Third Amended and Restated Certificate of Incorporation were each filed with the Secretary of State of the State of Delaware and effective on June 5, 2019, March 23, 2021, May 19, 2021, and February 9, 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The amendment to the Corporation's Third Amended and Restated Certificate of Incorporation set forth below was duly adopted in accordance with the provisions of Section 242 of the DGCL and has been consented to by the requisite vote of the stockholders of the Corporation at a meeting called in accordance with Section 222 of the DGCL.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Section 4.1 of **ARTICLE IV** of the Corporation's Third Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety to read as follows:

"**Section 4.1 <u>Authorized Capital Stock</u>**. The aggregate number of shares of all classes of capital stock that the Corporation is authorized to issue is One Hundred Fifty-Five Million (155,000,000) shares, consisting of (i) One Hundred Fifty Million (150,000,000) shares of common stock, par value $0.001 per share (the "<u>Common Stock</u>"), and (ii) Five Million (5,000,000) shares of preferred stock, par value $0.001 per share (the "<u>Preferred Stock</u>")."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The foregoing amendment shall be effective as of the time this Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware.

[*Signature Page Follows*]

State of Delaware Secretary of State Division of Corporations Delivered 12:51 PM 10/21/2025 FILED 12:51 PM 10/21/2025 SR 20254324607 – File Number 6823106

IN WITNESS WHEREOF, OS Therapies Incorporated has caused this Certificate of Amendment to be signed by its undersigned duly authorized officer, this 21st day of October 2025.

---

| | |
|:---|:---|
| **OS THERAPIES INCORPORATED** | **OS THERAPIES INCORPORATED** |
| By: | */s/ Paul A. Romness* |
| Name: | Paul A. Romness |
| Title: | President and Chief Executive Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

October 31, 2025

OS Therapies Incorporated

115 Pullman Crossing Road, Suite 103

Grasonville, Maryland 21638

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We have acted as counsel to OS Therapies Incorporated, a Delaware corporation (the "Company"), in connection with the filing with the Securities and Exchange Commission (the "Commission") of the Company's Registration Statement on Form S-8 (the "Registration Statement") relating to the registration of 6,000,000 shares (the "Shares") of the Company's common stock, par value $0.001 per share, issuable pursuant to the terms of and in the manner set forth in the Company's 2023 Incentive Compensation Plan, as amended (the "Plan").

This opinion letter is being delivered at the request of the Company and in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the "Securities Act").

We advise you that we have examined executed originals or copies certified or otherwise identified to our satisfaction of (i) the Registration Statement, (ii) the Company's Third Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as amended to date, (iii) the Plan and (iv) corporate proceedings of the Company, and such other documents, instruments and certificates of officers and representatives of the Company and of public officials, and we have made such examination of law, as we have deemed necessary or appropriate for purposes of the opinion expressed below.

We have assumed for purposes of rendering the opinion set forth herein, without any verification by us, the genuineness of all signatures, the legal capacity of all natural persons to execute and deliver documents, the authenticity and completeness of documents submitted to us as originals and the completeness and conformity with authentic original documents of all documents submitted to us as copies, and that all documents, books and records made available to us by the Company are accurate and complete.

On the basis of the foregoing and in reliance thereon and subject to the assumptions, qualifications and limitations set forth herein, we advise you that in our opinion, the Shares have been duly authorized and, when issued and paid for pursuant to the terms of and in the manner set forth in the Plan, will be validly issued, fully paid and non-assessable.

![](ex5-1_002.jpg)

October 31, 2025

We are members of the Bar of the State of New York. We express no opinion as to the effect of any laws other than the laws of the State of New York, the General Corporation Law of the State of Delaware and the federal laws of the United States of America, each as in effect on the date hereof.

This opinion speaks only at and as of its date and is based solely on the facts and circumstances known to us at and as of such date. We assume no obligation to revise or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in fact or law that may hereafter occur.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby concede that our firm is within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| */s/ Olshan Frome Wolosky LLP* |
| OLSHAN FROME WOLOSKY LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 31, 2025 with respect to the audited financial statements of OS Therapies Incorporated for the years ended December 31, 2024 and 2023.

*/s/ MaloneBailey, LLP*

www.malonebailey.com

Houston, Texas

October 31, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**OS Therapies Inc**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common stock, par value $0.001 per share | (1) |  | 6000000 | $1.89 | $11340000.00 | 0.0001381 | $1566.05 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $11340000.00 |  | 1566.05 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $1566.05 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents shares of common stock, par value $0.001 per share ("Common Stock"), of OS Therapies Incorporated, a Delaware corporation (the "Company"), issuable pursuant to the Company's 2023 Incentive Compensation Plan, as amended (the "Plan"). Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers such additional shares of Common Stock that may become issuable under the Plan by reason of any stock split, stock dividend, recapitalization or other similar transaction that results in an increase in the number of outstanding shares of Common Stock. Estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, based on the average of the high and low prices of the Common Stock as reported on the NYSE American on October 29, 2025.